💊 Treatment Type

JAK Inhibitor Clinical Trials UK

Find actively recruiting JAK inhibitor clinical trials in the UK. Explore how Janus kinase inhibitors are being tested for rheumatoid arthritis, psoriasis, inflammatory bowel disease, and other immune-mediated conditions.

Free to use — Live data from ClinicalTrials.gov — Updated hourly

What Are JAK Inhibitors?

JAK inhibitors (Janus kinase inhibitors) are a class of oral small-molecule drugs that block the JAK-STAT signalling pathway inside cells. This pathway is a key driver of inflammation in autoimmune and inflammatory diseases. By selectively blocking specific JAK enzymes (JAK1, JAK2, JAK3, or TYK2), these medicines can precisely target the inflammatory signals that cause disease. Since the approval of tofacitinib in 2012, JAK inhibitors have transformed treatment options for conditions that previously relied on injectable biologics.

Types of JAK Inhibitors in Clinical Trials

Pan-JAK Inhibitors

Drugs like tofacitinib that inhibit multiple JAK enzymes. Trials continue to explore their use in new indications and long-term safety. Effective but may have broader side effect profiles due to multi-target action.

Selective JAK1 Inhibitors

Upadacitinib and filgotinib target JAK1 specifically, aiming to maintain efficacy with fewer side effects. Trials test these in rheumatoid arthritis, Crohn's disease, ulcerative colitis, and atopic dermatitis.

JAK2/TYK2 Inhibitors

Ruxolitinib and deucravacitinib — used in myeloproliferative neoplasms (JAK2) and psoriasis (TYK2). Trials expand into graft-versus-host disease, vitiligo, and other inflammatory skin conditions.

Topical JAK Inhibitors

Creams and ointments containing ruxolitinib or other JAK inhibitors for localised skin conditions like vitiligo, atopic dermatitis, and alopecia areata. Topical delivery reduces systemic exposure and side effects.

Next-Generation Selective Inhibitors

New compounds with even greater selectivity for individual JAK isoforms or specific tissues. Trials aim to improve the safety profile while maintaining or enhancing therapeutic effect.

Combination Regimens

Trials testing JAK inhibitors alongside biologics, conventional immunosuppressants, or other targeted therapies. Particularly active in inflammatory bowel disease and transplant medicine.

Conditions Using JAK Inhibitors in Trials

JAK inhibitors are investigated in trials across many inflammatory and immune-mediated conditions. Select a condition to explore relevant trials:

🦴 Rheumatoid Arthritis 🟥 Psoriasis 🫀 Crohn's Disease 🫀 Ulcerative Colitis 🐺 Lupus 🧴 Eczema / Atopic Dermatitis 🩸 Haematology 🩸 Leukaemia 🧠 Multiple Sclerosis 🫁 Asthma

FAQs About JAK Inhibitor Trials

What are JAK inhibitors and how do they work?
JAK inhibitors block Janus kinase enzymes (JAK1, JAK2, JAK3, TYK2) inside cells. These enzymes are part of the JAK-STAT signalling pathway that drives inflammation in many autoimmune diseases. By blocking specific JAK enzymes, these oral drugs reduce the overactive immune response that causes conditions like rheumatoid arthritis, psoriasis, and inflammatory bowel disease.
What are the advantages of JAK inhibitors over biologics?
JAK inhibitors are taken orally as tablets, unlike most biologics which require injections or infusions. They work intracellularly, targeting a different part of the inflammatory pathway. Some patients who don't respond to biologics may respond to JAK inhibitors. However, JAK inhibitors can have different safety considerations, including infection risk and blood clot concerns, which clinical trials closely monitor.
Are JAK inhibitors safe?
JAK inhibitors have been extensively studied in clinical trials and several are approved for use. Like all immunosuppressive medicines, they carry risks including increased infection risk. Recent regulatory reviews have highlighted potential cardiovascular and blood clot risks in certain patient groups, particularly older patients with cardiovascular risk factors. Clinical trials continue to refine which patients benefit most and how to minimise risks.
Can JAK inhibitors be used for conditions other than autoimmune disease?
Yes. While JAK inhibitors are primarily known for autoimmune conditions, they are also being studied in clinical trials for certain blood cancers (myelofibrosis, polycythaemia vera), skin conditions (vitiligo, alopecia areata), and transplant rejection prevention. The JAK-STAT pathway is involved in many disease processes beyond autoimmunity.

Related Treatment Types

🧬 Biologics

The injectable alternative — monoclonal antibodies targeting the same inflammatory pathways

🎯 Targeted Therapy

Broader category of precision treatments including JAK inhibitors and other small-molecule targeted drugs

💊 Chemotherapy

Some JAK inhibitors are tested alongside chemotherapy in blood cancers

🩸 Stem Cell Transplant

JAK inhibitors used before or after transplant for GVHD prevention

Ready to Find JAK Inhibitor Trials?

Use our Smart Matcher to find actively recruiting JAK inhibitor trials tailored to your condition and treatment history.

🔍 Search JAK Inhibitor Trials